Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: An analysis of patients enrolled in the multicenter unsustained tachycardia trial

Circulation

Volumn 106, Issue 19, 2002, Pages 2466-2472

  Buxton, Alfred E ^a   Lee, Kerry L ^a   Hafley, Gail E ^a   Wyse, D George ^a   Fisher, John D ^a   Lehmann, Michael H ^a   Pires, Luis A ^a   Gold, Michael R ^a   Packer, Douglas L ^a   Josephson, Mark E ^a   Prystowsky, Eric N ^a   Talajic, Mario R ^a  

^a RHODE ISLAND HOSPITAL   (United States)

Author keywords

Death, sudden; Electrophysiology; Risk factors

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ELECTROPHYSIOLOGY; HEART ARREST; HEART ARRHYTHMIA; HEART DEATH; HEART EJECTION FRACTION; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SUDDEN DEATH; TACHYCARDIA;

CANADA; CARDIAC PACING, ARTIFICIAL; CHRONIC DISEASE; COMORBIDITY; CORONARY ARTERIOSCLEROSIS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; HUMANS; MULTICENTER STUDIES; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; SURVIVAL RATE; TACHYCARDIA, VENTRICULAR; UNITED STATES;

EID: 0037027503     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000037224.15873.83     Document Type: Article

References (28)

1. The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med. 1983;309:331-336.
2. Califf RM, Pieper KS, Lee KL, et al. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the Global Utilization of Streptokinase and tPA for Occluded Coronary Arteries Trial. Circulation. 2000;101:2231-2238.
3. Burns RJ, Gibbons RJ, Yi Q, et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol. 2002;39:30-36.
4. Buxton AE, Lee KL, DiCarlo L, et al, for the Multicenter Unsustained Tachycardia Trial Investigators. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. N Engl J Med. 2000;342:1937-1945.
5. Goldstein S, Friedman L, Hutchinson R, et al. Timing, mechanism and clinical setting of witnessed deaths in postmyocardial infarction patients. J Am Coll Cardiol. 1984;3:111-1117.
6. Rouleau JL, Talajic M, Sussex B, et al. Myocardial infarction patients in the 1990s: Their risk factors, stratification and survival in Canada: The Canadian Assessment of Myocardial Infarction (CAMI) study. J Am Coll Cardiol. 1996;27:1119-1127.
7. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: Mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J. 1989;117:151-159.
8. Pires LA, Lehmann MH, Steinman RT, et al. Sudden death in implantable cardioverter-defibrillator recipients: Clinical context, arrhythmic events and device responses. J Am Coll Cardiol. 1999;33:24-32.
9. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.
10. Moss AJ. Implantable cardioverter defibrillator therapy: The sickest patients benefit the most. Circulation. 2000;101:1638-1640.
11. Moss AJ, Fadl Y, Zareba W, et al. Survival benefit with an implanted defibrillator in relation to mortality risk in chronic coronary heart disease. Am J Cardiol. 2001;88:516-520.
12. Domanski M, Saksena S, Epstein A, et al. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. J Am Coll Cardiol. 1999;34:1090-1095.
13. Buxton AE, Fisher JD, Josephson ME, et al. Prevention of sudden death in patients with coronary artery disease: The Multicenter Unsustained Tachycardia Trial (MUSTT). Prog Cardiovasc Dis. 1993;36:215-226.
14. Hinkle LE, Thaler HT. Clinical classification of cardiac deaths. Circulation. 1982;65:457-464.
15. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
16. Cox D. Regression models and life-tables (with discussion). J R Stat Soc [B]. 1972;34:187-220.
17. Harrell F, Lee K, Pollack B. Regression models in clinical studies: Determining relationships between predictors and response. J Natl Cancer Inst. 1988;80:1198-1202.
18. Smith P. Splines as a useful and convenient statistical tool. Am Stat. 1979;33:57-62.
19. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, NY: John Wiley & Sons; 1987.
20. Schafer JL. Analysis of Incomplete Multivariate Data. London, UK: Chapman & Hall; 1997.
21. Tomaselli G, Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res. 1999;42:270-283.
22. Nuss H, Kaab S, Kass D, et al. Cellular basis of ventricular arrhythmias and abnormal automaticity in heart failure. Am J Physiol. 1999;277:H80-H91.
23. Bansch D, Castrucci M, Bocker D, et al. Ventricular tachycardias above the initially programmed tachycardia detection interval in patients with implantable cardioverter-defibrillators: Incidence, prediction and significance. J Am Coll Cardiol. 2000;36:557-565.
24. Freedberg NA, Hill JN, Fogel RI, et al. Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy: Implications for antiarrhythmic therapy and driving restrictions: Care Group. J Am Coll Cardiol. 2001;37:1910-1915.
25. Raitt MH, Dolack GL, Kudenchuk PJ, et al. Ventricular arrhythmias detected after transvenous defibrillator implantation in patients with a clinical history of only ventricular fibrillation: Implications for use of implantable defibrillator. Circulation. 1995;91:1996-2001.
26. Hallstrom A, Pratt C, Greene H, et al. Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: Analysis of the Cardiac Arrhythmia Suppression Trial. J Am Coll Cardiol. 1995;25:1250-1257.
27. Copie X, Hnatkova K, Staunton A, et al. Predictive power of increased heart rate versus depressed left ventricular ejection fraction and heart rate variability for risk stratification after myocardial infarction: Results of a two-year follow-up study. J Am Coll Cardiol. 1996;27:270-276.
28. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.